CA Patent

CA3096043A1 — Ret inhibitor for use in treating cancer having a ret alteration

Assigned to Blueprint Medicines Corp · Expires 2019-10-10 · 7y expired

What this patent protects

Disclosed herein is the treatment of a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of…

USPTO Abstract

Disclosed herein is the treatment of a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 300 mg to 400 mg of the selective RET inhibitor once daily.

Drugs covered by this patent

Patent Metadata

Patent number
CA3096043A1
Jurisdiction
CA
Classification
—
Expires
2019-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Blueprint Medicines Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.